Mucolase (Carbocisteine)

Carbocisteine, the active ingredient in Mucolase, is a mucolytic agent presented as an oral formulation for oral use. It is employed to reduce thickened respiratory secretions in patients with chronic bronchitis, COPD, asthma with mucus hypersecretion, and acute productive coughs.

GNH USA supplies Mucolase as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution in multiple jurisdictions. Its global network enables reliable, on‑time delivery to healthcare providers across Europe, Asia and the Americas.

Carbocisteine is used as a mucolytic to improve clearance of thickened airway secretions in several respiratory conditions.

- Chronic bronchitis: helps thin mucus, facilitating expectoration and reducing cough frequency. - Chronic obstructive pulmonary disease (COPD): reduces sputum viscosity, aiding airway patency and symptom control. - Asthma with mucus hypersecretion: assists in clearing excess mucus, improving airflow during exacerbations. - Acute respiratory tract infections with productive cough: promotes faster clearance of purulent secretions, supporting recovery.

Carbocisteine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild stomach discomfort or queasiness. - Diarrhea: loose stools, usually transient. - Dyspepsia: indigestion or upper abdominal pain. - Headache: mild to moderate head pain. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Allergic reactions: urticaria, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Severe gastrointestinal bleeding: uncommon but possible. - Hematologic abnormalities: eosinophilia or neutropenia.

When prescribing carbocisteine, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust use or monitor function in patients with reduced kidney clearance. - Hepatic disease: exercise caution in individuals with liver dysfunction. - Pregnancy: limited data; use only if potential benefit outweighs risk. - Breastfeeding: assess risk; drug may be excreted in milk. - Concomitant mucolytics: avoid simultaneous use with other mucolytic agents to prevent additive effects. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Carbocisteine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antitussives containing codeine: may counteract mucolytic action. - Highly protein‑bound drugs: carbocisteine can displace them, increasing free concentrations.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., macrolides): may increase gastrointestinal side effects. - Anticoagulants (warfarin): monitor INR as mucolytics can affect bleeding risk. - Bronchodilators (β2‑agonists): observe for additive respiratory effects.